MA61557B1 - Composés et compositions servant d'inhibiteurs de sppl2a - Google Patents
Composés et compositions servant d'inhibiteurs de sppl2aInfo
- Publication number
- MA61557B1 MA61557B1 MA61557A MA61557A MA61557B1 MA 61557 B1 MA61557 B1 MA 61557B1 MA 61557 A MA61557 A MA 61557A MA 61557 A MA61557 A MA 61557A MA 61557 B1 MA61557 B1 MA 61557B1
- Authority
- MA
- Morocco
- Prior art keywords
- inhibitors
- sppl2a
- compositions
- compounds
- peptidase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne des composés tricycliques comprenant une fraction diazépinone qui sont efficaces pour inhiber Sppl2a (peptidase 2a de type peptidase de peptide signal), des compositions pharmaceutiques contenant de tels inhibiteurs, et des procédés d'utilisation de tels inhibiteurs et de telles compositions.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063079604P | 2020-09-17 | 2020-09-17 | |
| EP21773886.3A EP4214210B1 (fr) | 2020-09-17 | 2021-09-15 | Composés et compositions servant d'inhibiteurs de sppl2a |
| PCT/IB2021/058398 WO2022058902A1 (fr) | 2020-09-17 | 2021-09-15 | Composés et compositions servant d'inhibiteurs de sppl2a |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA61557B1 true MA61557B1 (fr) | 2025-05-30 |
Family
ID=77897680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA61557A MA61557B1 (fr) | 2020-09-17 | 2021-09-15 | Composés et compositions servant d'inhibiteurs de sppl2a |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US20230365571A1 (fr) |
| EP (2) | EP4214210B1 (fr) |
| JP (2) | JP7771172B2 (fr) |
| KR (1) | KR20230069947A (fr) |
| CN (1) | CN116615425B (fr) |
| AU (1) | AU2021342783A1 (fr) |
| CA (1) | CA3192763A1 (fr) |
| CL (2) | CL2023000728A1 (fr) |
| CO (1) | CO2023004646A2 (fr) |
| CR (1) | CR20230142A (fr) |
| DK (1) | DK4214210T3 (fr) |
| DO (1) | DOP2023000055A (fr) |
| EC (1) | ECSP23027092A (fr) |
| ES (1) | ES3028668T3 (fr) |
| FI (1) | FI4214210T3 (fr) |
| GE (2) | GEP20257771B (fr) |
| HR (1) | HRP20250562T1 (fr) |
| HU (1) | HUE071569T2 (fr) |
| IL (2) | IL327099A (fr) |
| JO (1) | JOP20230044A1 (fr) |
| LT (1) | LT4214210T (fr) |
| MA (1) | MA61557B1 (fr) |
| MD (1) | MD4214210T2 (fr) |
| MX (1) | MX2023003122A (fr) |
| PE (1) | PE20231099A1 (fr) |
| PL (1) | PL4214210T3 (fr) |
| PT (1) | PT4214210T (fr) |
| RS (1) | RS66874B1 (fr) |
| SI (1) | SI4214210T1 (fr) |
| SM (1) | SMT202500216T1 (fr) |
| WO (1) | WO2022058902A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116947813A (zh) * | 2023-07-06 | 2023-10-27 | 绍兴贝斯美化工股份有限公司 | 一种3-氯-4-氨基-1-(3-吡啶基)-1h-吡唑的制备方法 |
| WO2025175102A1 (fr) | 2024-02-15 | 2025-08-21 | Incyte Corporation | Inhibiteurs de sppl2a |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2124503C1 (ru) * | 1992-05-18 | 1999-01-10 | И.Р.Сквибб энд Санз, Инк. | Гетероциклические азотсодержащие производные карбоновой кислоты, способ их получения и фармацевтическая композиция |
| GB9612622D0 (en) | 1996-06-17 | 1996-08-21 | Zeneca Ltd | Chemical process |
| US6432944B1 (en) | 2000-07-06 | 2002-08-13 | Bristol-Myers Squibb Company | Benzodiazepinone β-amyloid inhibitors: arylacetamidoalanyl derivatives |
| WO2004078163A2 (fr) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Compositions pharmaceutiques a base d'un co-cristal |
| BRPI0513310A (pt) | 2004-07-12 | 2008-05-06 | Idun Pharmaceuticals Inc | análogos de tetrapeptìdeo |
| US20060223849A1 (en) * | 2005-03-14 | 2006-10-05 | Mjalli Adnan M | Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors |
| AU2006255084A1 (en) | 2005-06-08 | 2006-12-14 | Novartis Ag | Organic compounds |
| KR20100037600A (ko) * | 2007-06-13 | 2010-04-09 | 브리스톨-마이어스 스큅 컴퍼니 | 응고 인자 억제제로서의 디펩티드 유사체 |
| WO2015160772A1 (fr) | 2014-04-15 | 2015-10-22 | Janssen Pharmaceutica Nv | Modulateurs tétrahydro-benzoimidazolyles de tgr5 |
| CN106146508A (zh) * | 2015-03-19 | 2016-11-23 | 浙江导明医药科技有限公司 | 优化的联合用药及其治疗癌症和自身免疫疾病的用途 |
| US11512080B2 (en) * | 2018-01-12 | 2022-11-29 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
-
2021
- 2021-09-15 RS RS20250568A patent/RS66874B1/sr unknown
- 2021-09-15 WO PCT/IB2021/058398 patent/WO2022058902A1/fr not_active Ceased
- 2021-09-15 CA CA3192763A patent/CA3192763A1/fr active Pending
- 2021-09-15 DK DK21773886.3T patent/DK4214210T3/da active
- 2021-09-15 PL PL21773886.3T patent/PL4214210T3/pl unknown
- 2021-09-15 CN CN202180074962.XA patent/CN116615425B/zh active Active
- 2021-09-15 GE GEAP202116217A patent/GEP20257771B/en unknown
- 2021-09-15 IL IL327099A patent/IL327099A/en unknown
- 2021-09-15 EP EP21773886.3A patent/EP4214210B1/fr active Active
- 2021-09-15 CR CR20230142A patent/CR20230142A/es unknown
- 2021-09-15 MX MX2023003122A patent/MX2023003122A/es unknown
- 2021-09-15 MA MA61557A patent/MA61557B1/fr unknown
- 2021-09-15 PT PT217738863T patent/PT4214210T/pt unknown
- 2021-09-15 EP EP25163259.2A patent/EP4578451A3/fr active Pending
- 2021-09-15 ES ES21773886T patent/ES3028668T3/es active Active
- 2021-09-15 FI FIEP21773886.3T patent/FI4214210T3/fi active
- 2021-09-15 HR HRP20250562TT patent/HRP20250562T1/hr unknown
- 2021-09-15 KR KR1020237011546A patent/KR20230069947A/ko active Pending
- 2021-09-15 PE PE2023001167A patent/PE20231099A1/es unknown
- 2021-09-15 MD MDE20230725T patent/MD4214210T2/ro unknown
- 2021-09-15 LT LTEPPCT/IB2021/058398T patent/LT4214210T/lt unknown
- 2021-09-15 SM SM20250216T patent/SMT202500216T1/it unknown
- 2021-09-15 SI SI202130298T patent/SI4214210T1/sl unknown
- 2021-09-15 AU AU2021342783A patent/AU2021342783A1/en active Pending
- 2021-09-15 GE GEAP202516217A patent/GEAP202516217A/en unknown
- 2021-09-15 US US18/044,455 patent/US20230365571A1/en active Pending
- 2021-09-15 HU HUE21773886A patent/HUE071569T2/hu unknown
- 2021-09-15 JP JP2023517751A patent/JP7771172B2/ja active Active
-
2023
- 2023-02-26 IL IL300953A patent/IL300953B2/en unknown
- 2023-02-27 JO JOJO/P/2023/0044A patent/JOP20230044A1/ar unknown
- 2023-03-14 CL CL2023000728A patent/CL2023000728A1/es unknown
- 2023-03-16 DO DO2023000055A patent/DOP2023000055A/es unknown
- 2023-04-14 CO CONC2023/0004646A patent/CO2023004646A2/es unknown
- 2023-04-14 EC ECSENADI202327092A patent/ECSP23027092A/es unknown
-
2024
- 2024-04-29 CL CL2024001312A patent/CL2024001312A1/es unknown
-
2025
- 2025-11-05 JP JP2025186205A patent/JP2026041723A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA62912A1 (fr) | Inhibition de la protéase 1 spécifique de l'ubiquitine (usp1) | |
| MA30526B1 (fr) | Inhibiteurs de prolyle hydroxylase | |
| TNSN04159A1 (fr) | Synthese controlee de ziprasidone et compositions en contenant | |
| MA44851B1 (fr) | Dérivés pyridinyltriazole substitués par des groupements amides et leurs utilisations | |
| TNSN99001A1 (fr) | Indoles 2,3-substitues servant d'agents anti-inflammatoires et analgesiques | |
| MA40893A (fr) | Dérivés de phényltriazole à substitution hydroxyalkyle et utilisations associées | |
| MA29160B1 (fr) | Derives de triazole substitues, servant d'antagonistes d'ocytocine | |
| MA52492B1 (fr) | Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés | |
| TNSN00010A1 (fr) | DIPHENYLUREE A SUBSTITUTION ω CARBOXYARYLE SERVANT D'INHIBUTEURS DE RAF KINASE. | |
| TNSN99172A1 (fr) | 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| TNSN98182A1 (fr) | Agonistes de prostaglandines nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| MA51204B1 (fr) | Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique | |
| MA30084B1 (fr) | Triazolopyridazines en tant que modulateurs de la tyrosine kinase | |
| MA29672B1 (fr) | [3.1.0] hétéroarylamides bicycliques servant d'inhibiteurs du transport de glycine de type I | |
| TNSN08196A1 (fr) | Derives de pyrazine | |
| TNSN06210A1 (fr) | Nitro-oxydérivés de prostaglandines | |
| TNSN99055A1 (fr) | Derives bicycliques d'acide hydroxamique nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| TN2009000204A1 (fr) | Spirocetones servant d'inhibiteurs d'acetyl-coa-carboxylase | |
| TNSN06051A1 (fr) | Derives de piperazine pour le traitement d'infections par le hiv | |
| TNSN02015A1 (fr) | Composes nouveaux antagonistes de ppar, et compositions les contenant | |
| MA26770A1 (fr) | Diarylamines substituees par 1-heterocycle. | |
| TN2009000033A1 (fr) | Derives de pyrazole servant d'inhibiteurs du cytochrome p450 | |
| Ospelt et al. | Inhibition of fibroblast activation protein and dipeptidylpeptidase 4 increases cartilage invasion by rheumatoid arthritis synovial fibroblasts | |
| TNSN98140A1 (fr) | Derives d'indole inhibiteurs de cyclo-oxygenase, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| DE69837324D1 (de) | Behandlung der multiplen sklerose durch einnahme von copolymer-1 |